How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

about

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

Item

http://www.wikidata.org/entity/Q35866147

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

@ast

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

@en

type

Item

label

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

@ast

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

@en

prefLabel

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

@ast

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

@en

P1476

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

@en

P2093

Aaron N Winn

http://www.w3.org/2001/XMLSchema#string

G Caleb Alexander

http://www.w3.org/2001/XMLSchema#string

Haiden A Huskamp

http://www.w3.org/2001/XMLSchema#string

James D Chambers

http://www.w3.org/2001/XMLSchema#string

Nancy L Keating

http://www.w3.org/2001/XMLSchema#string

Rachel A Freedman

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.

Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

Decline in the use of anthracyclines for breast cancer

The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.

Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.

The impact of Medicare coverage policies on health care utilization

Geographic variation in physicians' responses to a reimbursement change.

P304

313-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JOP.2015.004218

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stacie B. Dusetzina

Rena Conti

S Ellis

P577

2015-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26060224

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

4507391

http://www.w3.org/2001/XMLSchema#string